Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2007
Date:2/19/2008

(14,935) (3,392)

Preference shareholders - (5,368)

Earnings per share for result

attributable to the equity holders of

the Company during the period

(expressed in Euro per share)

Basic and diluted earnings per share (1.28) (1.94)

Consolidated balance sheet

(after appropriation of result)

(In EUR x 1,000)

31 December 2007 31 December 2006

ASSETS

Non-current assets

Intangible assets 1,897 1,540

Property, plant and equipment 2,102 1,091

3,999 2,631

Current assets

Receivables from related parties 985 1,202

Social security and other taxes 714 276

Other receivables 1,211 51

Cash and cash equivalents 51,330 14,058

54,240 15,587

Total assets 58,239 18,218

EQUITY

Shareholders' equity 51,407 (1,682)

Total group equity 51,407 (1,682)

LIABILITIES

Non-current liabilities

Loans from related parties - 1,038

Liabilities to preference shareholders - 15,504

Financial lease liabilities 402 498

Other non-current liabilities 604 45

1,006 17,085

Current liabilities

Trade
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
3. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
4. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
5. Acrongenomics on Track to Acquire Molecular Vision
6. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
7. Acrongenomics Acquires Equity Stake in Molecular Vision
8. The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit
9. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
10. Peakdale Molecular Announces GBP 1 Million Funding to Support Expansion and Growth
11. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
Post Your Comments:
*Name:
*Comment:
*Email: